Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Prostate Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Prostate Cancer
    TopAbstracts in Prostate Cancer 10/28/2009 - (DGNews)
    Rethinking screening for breast cancer and prostate cancer - (JAMA)
    Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy - (JAMA)
    TopAbstracts in Prostate Cancer 10/14/2009 - (DGNews)
    Minimally Invasive Radical Prostatectomy Has Some Advantages, But Higher Rate of Complications - (DGNews)

    News archive

     Recent webcasts/CME - Prostate Cancer
    • Exploring the Link Between Hypogonadism and Metabolic Comorbidities
    • Prostate Cancer: Recent Developments Relevant for Internal Medicine Physicians
      Finasteride and Prostate Cancer Prevention: The Latest Chapter
      Finasteride and Prostate Cancer Prevention: The Latest Chapter
      Emerging Research May Improve Prostate Cancer Treatment

      Webcasts/CME archive

       Recent cases - Prostate Cancer
        Incidental Carcinoma of the Prostate Gland Presenting with Initial Manifestation of Disseminated Intravascular Coagulopathy (Dic) in a Middle Aged Man: A Case Report
        Non-Prostatic Pathology on Prostate Needle-Biopsy - Colorectal Carcinoid: A Case Report
        A 70-Year-Old Male Having Advanced Prostate Cancer Presenting with Hypercalcemia and Diffuse Osteoblastic Bone Metastases: A Case Report
        A Dramatic, Objective Antiandrogen Withdrawal Response: Case Report and Review of the Literature
        Anejaculation as an Atypical Presentation of Prostate Cancer: A Case Report

        Cases archive
          




        my personal edition > prostate cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        AZD2171 Well Tolerated in Patients with Advanced Prostate Cancer: Presented at AACR-NCI-EORTC

        By Maggie Schwarz

        PHILADELPHIA, PA -- November 18, 2005 -- Early data on the investigational agent, AZD2171, show the drug has broad-spectrum antitumor activity in a range of xenograft models, consistent with potent inhibition of vascular endothelial growth factor (VEGF) signaling and angiogenesis.

        The agent, an oral, selective and reversible inhibitor of VEGF receptor signaling, appears to be generally well tolerated at doses up to 20 mg/day in patients with advanced prostate cancer.

        Lead investigator Charles Ryan, Assistant Clinical Professor, University of California, San Francisco, San Francisco, California, United States, presented the findings from an ongoing, phase 1, multicenter, open-label dose escalation trial here on November 16th at the International Conference on Molecular Targets and Cancer Therapeutics.

        The conference was organized jointly by the American Association for Cancer Research - National Cancer Institute - European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC).

        The trial was designed to assess the safety and tolerability of AZD2171 in patients with advanced prostate adenocarcinoma.

        Dr. Ryan and colleagues recruited 24 patients with advanced prostate carcinoma from three centers in the United States. Patients have received once-daily oral doses of AZD2171 (1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 30 mg) in continuous 21-day treatment cycles until a withdrawal criterion is met (disease progression, dose-limiting toxicity or voluntary discontinuation by the patient). No intra-patient dose escalation has occurred.

        The researches have determined objective response rate using the Response Evaluation Criteria in Solid Tumors (RECIST) and changes in prostate-specific antigen (PSA) levels.

        No objective tumor responses have been observed among the 14 patients with bi-dimensionally measurable disease. Four patients had a RECIST-defined best response of stable disease (10 mg, n = 1; 20 mg, n = 3).

        No PSA responses have been observed to date. However, a PSA decline of less than 50% was observed in two patients. The PSA decline ranged from 22% to 36% between cycles 1 and 4 in one patient (20 mg) and was 26% on day 8 of cycle 1 in the second patient (30 mg).

        A 30-day follow-up after the termination of treatment showed that one patient in the 20 mg cohort experienced a reduction in PSA levels greater than 50% from baseline. PSA levels increased from 68.14 ng/mL at baseline to 73.89 ng/mL at the time of treatment discontinuation.

        However, after 30 days of follow-up, PSA levels declined to 3.28 ng/mL, which was confirmed on repeated testing. Examination of the corresponding CT scan from this patient revealed resolution of retroperitoneal adenopathy. This patient remains free from further disease progression 6 months after stopping treatment and has received no further antitumor therapy.

        Dr. Ryan concluded that the PSA changes and off-study objective response are encouraging. He asserted that AZD2171 merits further investigation in the treatment of prostate cancer.


        [Presentation title: Phase I Evaluation of AZD2171, a Highly Potent VEGFR Tyrosine Kinase Inhibitor, in Patients with Advanced Prostate Carcinoma. Abstract A4]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send